Q2 Earnings Update: bluebird bio (BLUE) and Regeneron (REGN)

how to buy gabapentin online Q2 Earnings Updates: BLUE,REGN Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. U.S.Eyelea sales grew 8% to$992M and global sales grew 13% to $1.66B.  Eczema drug Dupixent grew to $209M. Regeneron (REGN) recently hit its low for the year just this past May below $300! Back in early […]

Continue Reading 0

Rayno BioBeat #5: July 2018 Mid-Cap Momentum Fades With Rotation Into Large Caps-Healthcare Stocks Are Strong (XLV)…Updates

http://whiteearthdesign.co.uk/shop/?product_order=date Aug 1 Update…overall a good day Hot Mid-Caps: BPMC up 12.18%, NBIX up 13%, SRPT up 3.47% Large Cap Rayno Portfolio Movers: ABBV up 1.82%,  BIIB up 2.9%, BMY up 1.48% XLV Flat today after 6.2% run in July, FBIOX up 1.7% with LOXO,NBIX added ============= Momentum Faded Since Strong ASCO Rally Rotation into Large […]

Continue Reading 0

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

Deltasone for sale Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Hold and Ignore Rocky Week of Global Politics- Big Earnings Upcoming…Updates CELG, BIIB, AZN, XBI

7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9%  to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock drops 10% to $344.75 as […]

Continue Reading 0

Biotechs Cruise onto Green Screen: July Looks Good…Updates

Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck succumbs to Trump pricing pressure with a minor Hep-C drug. Mid-caps mainly green, large caps […]

Continue Reading 0

Biotech Rally Buffeted By Trump Tweet But Gains Hold…Update-2

Update-2 …Futures Sink As Trade War Rhetoric Heats Up: China Responds to Trump Additional $200B in tariffs on Chinese goods that may get hit with tariffs-See Bloomberg updates. China will take countermeasures-strongly opposed US action. Nikkei hit hardest down 2.1%. China commerce ministry official says US tariff plan hurts WTO system. ============= Update-1… Biotech Stocks […]

Continue Reading 0

Biotech Momentum Is Boosted by Biogen’s Alzheimer Disease Drug Results

Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting  Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late June. Rally is just short of hitting new 2018 highs in the sector. Biotech stocks  rallied with […]

Continue Reading 0

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Rayno BioBeat #4 2018: ASCO Biotech Momentum Continues with M&A Theme…Updates 6/29

Momentous  Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]

Continue Reading 0

Rayno Life Science Portfolio Flash Update: Roche and FMI Merger; Update with XBI breakout

Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50 in the pre-market. We added FMI to our top picks on […]

Continue Reading 0